The findings of a study published last week by the journal Neuropsychopharmacology “provide proof of principle supporting potential of CBD [cannabidiol] in relapse prevention”. “Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, has received attention for therapeutic potential in treating neurologic and psychiatric disorders”, states the study’s abstract. “Recently, CBD has also been explored for potential …
